Skip to content

Welcome to Discover Pharma! Today is : November 6, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Advanced Therapies

  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    AAVantgarde completes enrollment in LUCE-1 Phase 1 and Phase 2 trial of gene therapy AAVB-081 for Usher syndrome type 1B

    AAVantgarde Bio has completed enrollment in LUCE-1, a first-in-human Phase [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics

    iXCells names Steve Smith CEO to advance human iPSC preclinical services

    iXCells Biotechnologies has appointed Steve Smith as chief executive officer, [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Enhanced Genomics appoints Katerina Leftheris to board of directors

    Enhanced Genomics has appointed Katerina Leftheris to its board of [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Pharmaceuticals and therapeutics

    NanoSyrinx appoints Thomas Farrell as CEO

    NanoSyrinx has appointed Thomas Farrell as chief executive officer and [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Bicara announces Phase 3 optimal dose for ficerafusp alfa and provides 2026 corporate outlook

    Bicara Therapeutics has selected 1500 mg of ficerafusp alfa as [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development

    Nuclera extends Series C funding to $87M to advance antibody engineering

    Nuclera has extended its Series C funding to a total [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development,Genomics and sequencing,Therapeutic Areas

    PacBio HiFi adopted to study sudden unexplained death in childhood and advance precision therapies for rare diseases

    PacBio is supporting two research initiatives that use its HiFi [...]

    May 5, 2026
  • Advanced Therapies,Clinical & Regulatory,Manufacturing & Supply Chain

    FDA clears IND amendment for automated manufacturing of Cabaletta’s rese-cel using Cellares platforms

    Cellares has secured FDA clearance of an IND amendment allowing [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Bio‑Sourcing and Zerion Pharma collaborate on first oral HER2 monoclonal antibody

    Bio‑Sourcing and Zerion Pharma have joined forces to develop the [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development,Pharmaceuticals and therapeutics

    FairJourney Bio launches cryo-EM services from San Diego laboratories

    FairJourney Bio (FJBio) has expanded its portfolio with the launch [...]

    May 5, 2026
Previous111213Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Novadip secures €10.4M to advance pivotal Phase 3 trial
    Categories: Advanced Therapies, Biotech & Pharma Business, Clinical & Regulatory, Research & Development, Therapeutic Areas
  • Telix to acquire ITM in $1.65BN radiopharmaceutical deal
    Categories: Biotech & Pharma Business, Manufacturing & Supply Chain, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Andelyn to manufacture FDA-approved Fayuvi gene therapy for Sanfilippo syndrome
    Categories: Advanced Therapies, Biotech & Pharma Business, Central Nervous System, Clinical & Regulatory, Manufacturing & Supply Chain, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top